LAST Innovation

LAST Innovation is a preclinical-stage Canadian biotechnology company focused on developing next-generation radiopharmaceuticals for oncology indications, with a primary focus on prostate cancer. Co-founded by Dr. Yuzhuo Wang and collaborators from the University of British Columbia (UBC) and BC Cancer, the company leverages proprietary technology licensed from the Vancouver Prostate Centre. Its lead program involves the development of novel derivatives of the prostate cancer radiopharmaceutical Pluvicto, engineered with a built-in albumin-binding moiety. This modification is designed to prolong blood circulation time, thereby increasing drug accumulation in tumor lesions and enhancing therapeutic efficacy. Backed by approximately $2.5 million in angel funding, LAST Innovation aims to address the limitations of current PSMA-targeted radiotherapies.